Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

GOSSBullishCorporate Developmentsnews

High materiality8/10

Gossamer regains PAH rights; NDA timing remains key catalyst for 2027

Jul 27, 2026, 2:31 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive corporate actions and potential NDA progression imply upside sensitivity to regulatory milestones and increased control over assets, though the key catalyst (FDA decision) is 2–12 quarters away and remains binary.

AI summary

What happened, with direct paths to the underlying reporting

Gossamer Bio regains full global rights to its PAH candidate after terminating its collaboration with Chiesi, complemented by balance-sheet restructuring. The FDA view of PROSERA as a review issue supports an NDA filing using PROSERA and TORREY data, with a potential Q3 2027 approval, contingent on acceptability. With about $57M in cash and meaningful debt reduction, the setup improves optionality for investors.

Gossamer regains full global rights to PAH candidate after ending Chiesi deal.
NDA planned using PROSERA data; potential approval in 3Q2027 if filed.
Chiesi to pay $5 million; royalties and milestones on sales.
Debt reduced by about $115.9 million; 2027 notes balance $18.9 million.
Share price up 44% to $0.19; near 52-week low around $0.11.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Gossamer regains PAH rights; NDA timing remains key catalyst for 2027

Gossamer Bio's Stock Drops After Phase 3 Study Results

Gossamer Bio's Drug Fails Late-Stage Study, Implications for Investors